BNTX240517C87500
- 4.30
- 0.000.00%
BioNTech Newsroom
Moderna, CureVac, Other Vaccine Stocks Jump as New Human Bird-flu Cases Reported in U.S., Australia
Vaccine-related stocks moved sharply higher Wednesday as new human bird-flu cases were reported in the U.S. and Australia.
The spread of avian influenza sparks fears that US vaccine stocks such as Moderna (MRNA.US) rose sharply
US vaccine stocks rose sharply on Wednesday.
Moderna, BioNTech Close With Double-digit Percentage Gains Amid Bird Flu Fears
Health Care Up as Vaccine Makers Gain - Health Care Roundup
Health-care companies rose as reported cases of bird flu in Australia and the U.S. buoyed vaccine makers. Shares of CureVac, BioNTech and Moderna rose by 10% or more after new human bird-flu cases we
Experts Predict Rise In COVID-19 Cases: Vaccine Stocks Climb
Shares of vaccine producers' stocks are trading higher Wednesday on reports indicating disease experts predict a small rise in COVID-19 cases this summer.The Details:According to a report from NBC New
COVID-19 Vaccine Makers Rebound Amid Post-pandemic Prospects
BioNTech Up Over 8%, on Pace for Largest Percent Increase Since October 2022 -- Data Talk
BioNTech SE Sponsored ADR (BNTX) is currently at $99.97, up $7.90 or 8.58% --Would be highest close since Jan. 23, 2024, when it closed at $100.29 --On pace for largest percent increase since Oct. 2
Express News | Shares of Vaccine Stocks Are Trading Higher on Reports Indicating Disease Experts Predict a Small Rise in COVID Cases This Summer
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading
European equities traded in the US as American depositary receipts fell Wednesday morning, declining 0.48% to 1,423.09 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led
Express News | 'Disease Experts Predict A Small Rise In Covid-19 Cases This Summer' - CNBC
Express News | BioNTech SE : Leerink Partners Cuts Target Price to $102 From $116
BioNTech Reveals Breakthroughs in Cancer Immunotherapy
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
MAINZ, Germany, May 21, 2024 – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will present clinical trial data for selected programs from the Company's diversified immuno-oncology pipeline at the American
Medigene, BioNTech Extend Cancer Immunotherapy Partnership
Medigene (MDG1.F) and pharmaceutical giant BioNTech (22UA.F) extended their three-year collaboration for the advancement of T cell receptor immunotherapies against cancer. The deal was originally sign
BioNTech Envisions Revolutionary Cancer Treatments
BioNTech | 6-K: Report of foreign private issuer (related to financial reporting)
Sector Update: Health Care Stocks Softer Friday Afternoon
Health care stocks eased Friday afternoon with the NYSE Health Care Index down 0.1% and the Health Care Select Sector SPDR Fund (XLV) marginally higher. The iShares Biotechnology ETF (IBB) fell 0.3%.
Sector Update: Health Care
Health care stocks eased Friday afternoon with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both down 0.1%. The iShares Biotechnology ETF (IBB) fell 0.4%. In corporate
Express News | BioNTech Says "Will Continue to Vigorously Defend" Its Innovations Against All Allegations of Patent Infringement Including Ep ‘949 Case
Express News | BioNTech Says "Believe That Neither Ep ‘949 nor Any of the Auxiliary Requests Filed by Moderna Meet the Requirements for Patentability" - Statement